Mesoblast off and running in EU with cardiovascular stem cell trial
This article was originally published in Scrip
Executive Summary
Australia's Mesoblast has got the go-ahead to start a European Phase IIb trial of its Revascor cardiovascular stem cell therapy. The study, called AMICI, will evaluate the off-the-shelf therapy in 225 heart attack patients in countries including the UK, the Netherlands and Belgium. Mesoblast plans to later expand the trial to include patients in other European countries, as well as the US and Australia.